Prostate-apoptosis-response-gene-4 increases sensitivity to TRAIL-induced apoptosis

被引:25
作者
Boehrer, S
Nowak, D
Puccetti, E
Ruthardt, M
Sattler, N
Trepohl, B
Schneider, B
Hoelzer, D
Mitrou, PS
Chow, KU
机构
[1] Univ Frankfurt Klinikum, Dept Med 2, D-60590 Frankfurt, Germany
[2] Univ Hosp Benjamin Franklin, Dept Med 3, D-12203 Berlin, Germany
[3] Med Versorgungszentrum, D-60596 Frankfurt, Germany
关键词
par-4; apoptosis; c-FLIPL; TRAIL; caspase-8;
D O I
10.1016/j.leukres.2005.09.003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The capacity of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) to preferentially induce apoptosis in malignant cells while sparing normal tissues renders it an attractive therapeutic agent. Nevertheless, the molecular determinants governing sensitivity towards TRAIL remain to be defined. Acknowledging the previously demonstrated deregulation of prostate-apoptosis-response-gene-4 (par-4) in ex vivo cells of patients suffering from acute and chronic lymphatic leukemia, we here tested the hypothesis that expression of par-4 influences sensitivity to TRAIL. Evaluating this hypothesis we show, that par-4-transfected T-lymphoblastic Jurkat cells exhibit a considerably increased rate of apoptosis upon incubation with an agonistic TRAIL-antibody as compared to their mock-transfected counterparts. Defining the underlying molecular mechanisms we provide evidence, that par-4 enhances sensitivity towards TRAIL by employing crucial members of the extrinsic pathway. Thus, par-4-overexpressing Jurkat clones show an enforced cleavage of c-Flip(L) together with an increased activation of the initiator caspases-8 and -10. In addition, expression of par-4 enables cells to down-regulate the inhibitor-of-apoptosis proteins cIAP-1, cIAP-2, XIAP and survivin with a concomitantly enhanced activation of the executioner caspases-6 and -7. Supporting the crucial role of caspase-8 in par-4-promoted apoptosis we demonstrate that inhibition of caspase-8 considerably reduces TRAIL-induced apoptosis in par-4 and mock-transfected Jurkat clones and reverses the described molecular changes. In conclusion, we here provide first evidence that expression of par-4 in neoplastic lymphocytes augments sensitivity to TRAIL-induced cell death and outline the responsible molecular mechanisms, in particular the crucial role of caspase-8 activation. (C) 2006 Published by Elsevier Ltd.
引用
收藏
页码:597 / 605
页数:9
相关论文
共 50 条
[1]  
ABE K, 2000, COMPLEXITY TNF RELAT, P52
[2]   Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy [J].
Almasan, A ;
Ashkenazi, A .
CYTOKINE & GROWTH FACTOR REVIEWS, 2003, 14 (3-4) :337-348
[3]   Safety and antitumor activity of recombinant soluble Apo2 ligand [J].
Ashkenazi, A ;
Pai, RC ;
Fong, S ;
Leung, S ;
Lawrence, DA ;
Masters, SA ;
Blackie, C ;
Chang, L ;
McMurtrey, AE ;
Hebert, A ;
DeForge, L ;
Koumenis, IL ;
Lewis, D ;
Harris, L ;
Bussiere, J ;
Koeppen, H ;
Shahrokh, Z ;
Schwall, RH .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (02) :155-162
[4]   Prostate apoptosis response gene-4 sensitizes neoplastic lymphocytes to CD95-induced apoptosis [J].
Bergmann, M ;
Kukoc-Zivojnov, N ;
Chow, KU ;
Trepohl, B ;
Hoelzer, D ;
Weidmann, E ;
Mitrou, PS ;
Boehrer, S .
ANNALS OF HEMATOLOGY, 2004, 83 (10) :646-653
[5]   Death effector domain-containing herpesvirus and poxvirus proteins inhibit both Fas- and TNFR1-induced apoptosis [J].
Bertin, J ;
Armstrong, RC ;
Ottilie, S ;
Martin, DA ;
Wang, Y ;
Banks, S ;
Wang, GH ;
Senkevich, TG ;
Alnemri, ES ;
Moss, B ;
Lenardo, MJ ;
Tomaselli, KJ ;
Cohen, JI .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (04) :1172-1176
[6]   The short splice form of Casper/c-FLIP is a major cellular inhibitor of TRAIL-induced apoptosis [J].
Bin, LH ;
Li, XY ;
Xu, LG ;
Shu, HB .
FEBS LETTERS, 2002, 510 (1-2) :37-40
[7]   TRAIL receptor-2 signals apoptosis through FADD and caspase-8 [J].
Bodmer, JL ;
Holler, N ;
Reynard, S ;
Vinciguerra, P ;
Schneider, P ;
Juo, P ;
Blenis, J ;
Tschopp, J .
NATURE CELL BIOLOGY, 2000, 2 (04) :241-243
[8]  
Boehrer S, 2001, Hematol J, V2, P103, DOI 10.1038/sj.thj.6200089
[9]  
Boehrer S, 2002, CANCER RES, V62, P1768
[10]  
Boghaert ER, 1997, CELL GROWTH DIFFER, V8, P881